Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SZJK-0421
- Development stage
- Phase 1
- Lead developer
- Shenzhen Jikang Pharmaceutical Technology
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
SZJK-0421 is an orally bioavailable small molecule inhibitor of WEE1 kinase, currently being developed by Shenzhen Jikang Pharmaceutical Technology for the treatment of advanced malignancies. WEE1 is a key regulator of the G2/M checkpoint in the cell cycle; by inhibiting WEE1, the drug promotes premature entry into mitosis in cells with DNA damage (particularly those with TP53 mutations), leading to mitotic catastrophe and apoptosis. The drug is currently in Phase 1 clinical trials in China, specifically targeting advanced gynecologic malignancies (such as endometrial and ovarian cancers) and soft tissue sarcomas.
02
Targets
XPO1 (Exportin-1)WEE1 (WEE1 G2 checkpoint kinase)
Beyond the preview
Go deeper on SZJK-0421.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SZJK-0421.